• PhD in molecular biology, genetics, bioinformatics, or a related field

• Strong background in NGS-based genomics and/or computational genomics

• Experience with cancer genomics, liquid biopsy, or immune profiling is an advantage

• Motivation to work in translational, collaborative research projects with clinical impact

• Excellent communication skills in English, both written and spoken

The University Hospital of Tübingen is one of the leading university hospitals in Europe contributing to high-performance medicine, research and teaching. More than 10,000 cancer patients are treated every year at the local Comprehensive Cancer Center (CCC), which consists of 14 different institutes, the Center for Personalized Medicine and the National Center for Tumor diseases Tübingen. As part of the CCC, the Institute of Medical Genetics and Applied Genomics focuses on the application of Next-Generation Sequencing for tumor genome and transcriptome analysis (available technologies include Illumina NovaSeq X Plus, Oxford Nanopore PromethION) and computational genomics methods. The oncogenetics group uses state-of-the-art tumor methods to analyze tumor profiles (whole exome and genome sequencing), monitor response to treatment (liquid biopsy), predict response to immunotherapy (single-cell RNA sequencing), classify tumor variants using clinical decision support systems, and analyze tumor heterogeneity and immune cell repertoire.